Canakinumab reduces risk of cardiovascular events in populations with unmet clinical need Two new analyses of data from more than 10,000 heart attack survivors worldwide were presented at a recent meeting. Scientists assessed whether the anti-inflammatory therapy canakinumab reduced rates of major adverse cardiovascular events and co-morbidities among high-risk atherosclerotic patients with chronic kidney disease (CKD) or those with pre-diabetes/diagnosed type 2 diabetes, respectively. http://ift.tt/eA8V8J
Monday 12 March 2018
Tags
# Latest Science News -- ScienceDaily
![Author Image]()
About Unknown
Templatesyard is a blogger resources site is a provider of high quality blogger template with premium looking layout and robust design. The main mission of templatesyard is to provide the best quality blogger templates which are professionally designed and perfectlly seo optimized to deliver best result for your blog.
Subscribe to:
Post Comments (Atom)
Hello, my name is Jack Sparrow. I'm a 50 year old self-employed Pirate from the Caribbean.
No comments:
Post a Comment